Clinical Trials Logo

Clinical Trial Summary

INTENSE-TBM is randomized controlled, phase III, multicenter, 2 x 2 factorial plan superiority trial assessing the efficacity of two interventions to reduce mortality from tuberculous meningitis (TBM) in adolescents and adults with or without HIV-infection in sub-Saharan Africa: - Intensified TBM treatment with high-dose rifampicin and linezolid, compared to WHO standard TBM treatment. - Aspirin, compared to not receiving aspirin. The trial will be open-label for anti-TB treatment and placebo-controlled for aspirin treatment.


Clinical Trial Description

Settings: Côte d'Ivoire, Madagascar, Uganda, South Africa. Follow-up: Participants will be followed up for 40 weeks. Sample size: 768 patients (192 in each arm). Primary analysis: We will use a Cox proportional hazard ratio model to compare intensified TB treatment with WHO standard TB treatment, and aspirin with placebo, adjusting for the initial stratification variables (trial country, HIV status, British Medical Research Council |BMRC] severity grade). The primary analysis will be conducted in the intention to treat population. Sub-studies: - The PK-PD sub-study will take place in the 4 participating countries, and involve 40 participants in total. - The Multi-Omics sub-study will only take place in South-Africa. It will involve 160 participants in this country. Participants in each sub-study will sign a specific informed consent. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04145258
Study type Interventional
Source ANRS, Emerging Infectious Diseases
Contact Fabrice Bonnet, M.D., Ph.D.
Phone +33 (0)5 56 79 58 26
Email fabrice.bonnet@chu-bordeaux.fr
Status Recruiting
Phase Phase 3
Start date February 7, 2021
Completion date April 2026

See also
  Status Clinical Trial Phase
Completed NCT01371916 - Diagnosis of Tuberculous Meningitis by ESAT-6 in CSF N/A
Active, not recruiting NCT00433719 - Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis N/A
Completed NCT02237365 - A Pilot Study of Adjunctive Aspirin for the Treatment of HIV Negative Adults With Tuberculous Meningitis Phase 2
Not yet recruiting NCT02588196 - The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis Phase 4
Completed NCT03092817 - Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial) Phase 3
Recruiting NCT03787940 - Optimizing Antituberculosis Therapy in Adults With Tuberculous Meningitis N/A
Not yet recruiting NCT05917340 - Intensified Short Course Regimen for TBM in Adults Phase 3
Completed NCT01802502 - Rifampicin Explorative PK Study for Tuberculous Meningitis Comparing Oral and Intravenous Preparation Phase 2
Recruiting NCT05636254 - Diagnostic Accuracy of Imaging Findings in TBM/Spinal Tubercular Arachnoiditis and Correlation With Outcomes
Recruiting NCT03898635 - Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis
Completed NCT05781646 - Xpert MTB/RIF Assay for Diagnosis of Tuberculous Meningitis (TBM) in Maharaj Nakorn Chiang Mai Hospital N/A
Active, not recruiting NCT03100786 - Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis Phase 3
Recruiting NCT05383742 - Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis Phase 2
Completed NCT03226379 - Driving Reduced AIDS-associated Meningo-encephalitis Mortality N/A
Recruiting NCT05590455 - Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis Phase 2
Recruiting NCT04308928 - Evaluation of New Biomarker-based Approaches for Improving the Diagnosis of Childhood Tuberculous Meningitis